Browsing South African National Bioinformatics Institute (SANBI) by Author "Mikasi, Sello Given"
Now showing items 1-4 of 4
-
Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa
Cloete, Ruben; Obasa, Adetayo Emmanuel; Mikasi, Sello Given (Frontiers Media S.A., 2020)The South African national combination antiretroviral therapy (cART) roll-out program started in 2006, with over 4.4 million people accessing treatment since it was first introduced. HIV-1 drug resistance can hamper the ... -
HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy
Cloete, Ruben; Mikasi, Sello Given; Ikomey, George Mondinde (SAMA, 2020): The integrase (IN) strand-transfer inhibitor (InSTI) dolutegravir (DTG) is now recommended by the World Health Organization as part of salvage and/or first-line combination antiretroviral therapy (cART).[1] DTG has a ... -
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C integrase-dolutegravir binding
Chitongo, Rumbidzai; Obasa, Adetayo Emmanuel; Mikasi, Sello Given (Public Library of Science, 2020)Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand transfer inhibitors (INSTIs) have proven to be a ... -
Structural comparison of diverse HIV-1 subtypes using molecular modelling and docking analyses of integrase inhibitors
Isaacs, Darren; Mikasi, Sello Given; Obasa, Adetayo Emmanuel (MPDI, 2020)The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme targeted by several drugs; ...